21 Aug 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Australian firm AtCor Medical, a developer and marketer of the SphygmoCor system that measures central aortic blood pressures and arterial stiffness noninvasively, has signed a contract to supply its new SphygmoCor XCEL systems and clinical trial support services to a major international pharmaceutical company.
The system measures brachial and central aortic blood pressure simultaneously and was launched by AtCor Medical in May 2012. The value of the contract is approximately $1.1 million.
Mr Duncan Ross, CEO of AtCor Medical, said, "We are pleased to have secured this contract and delighted the customer has decided to use the new XCEL system, which greatly enhances ease of use while maintaining central aortic blood pressure waveform fidelity and data quality. XCEL further consolidates AtCor Medical's gold standard position with both researchers and clinicians.
Our product quality is matched by our reputation as a highly reliable provider of clinical trial support services to the pharmaceutical sector."